key: cord-0831000-zaratwac
authors: Pillaiyar, Thanigaimalai; Wendt, Lukas L.; Manickam, Manoj; Easwaran, Maheswaran
title: The recent outbreaks of human coronaviruses: A medicinal chemistry perspective
date: 2020-08-27
journal: Med Res Rev
DOI: 10.1002/med.21724
sha: 2566d35cac51a0b722e150703d777a62af337f71
doc_id: 831000
cord_uid: zaratwac

Coronaviruses (CoVs) infect both humans and animals. In humans, CoVs can cause respiratory, kidney, heart, brain, and intestinal infections that can range from mild to lethal. Since the start of the 21st century, three β‐coronaviruses have crossed the species barrier to infect humans: severe‐acute respiratory syndrome (SARS)‐CoV‐1, Middle East respiratory syndrome (MERS)‐CoV, and SARS‐CoV‐2 (2019‐nCoV). These viruses are dangerous and can easily be transmitted from human to human. Therefore, the development of anticoronaviral therapies is urgently needed. However, to date, no approved vaccines or drugs against CoV infections are available. In this review, we focus on the medicinal chemistry efforts toward the development of antiviral agents against SARS‐CoV‐1, MERS‐CoV, SARS‐CoV‐2, targeting biochemical events important for viral replication and its life cycle. These targets include the spike glycoprotein and its host‐receptors for viral entry, proteases that are essential for cleaving polyproteins to produce functional proteins, and RNA‐dependent RNA polymerase for viral RNA replication.

The interruption of any stage of the viral life cycle can become an important therapeutic approach for treating CoV-related diseases. A recent SARS-CoV-2-human protein-protein interaction analysis showed that SARS-CoV-2 contains approximately 66 druggable proteins, each of which has several ligand binding sites. 25 The most interesting coronavirus proteins are the S glycoprotein, proteases M pro and PL pro , RdRP, and helicase. In this 36 It is worth highlighting that a similar strategy could work for the new SARS-CoV-2. The recently solved cryo-EM structure of SARS-CoV-2 in complex with human ACE2 can provide a structural rationale for the peptide design. 29 For viral entry, MERS-CoV uses its spike protein (S) to interact with the host-receptor DPP4, [37] [38] [39] also known as adenosine deaminase-complexing protein-2 or CD26. 37 MERS-CoV was also the first virus reported to use this particular path. 35, 37 DPP4 is a type II transmembrane glycoprotein, that forms homodimers on the cell surface, and it is involved in the cleavage of dipeptides. 37, 40 In humans, DPP4 is predominantly found on the bronchial epithelial and alveolar cells in the lower lungs. 40 A heptad repeat (HR) is a repeating structural pattern of seven amino acids. A crucial membrane fusion framework of SARS-CoV is the 6-helix-bundle (6-HB) that is formed by HR1 and HR2 of the viral S protein.

Enfuvirtide (T-20) is an FDA approved HR2 peptide and the first HIV fusion inhibitor. It has opened up new avenues toward identifying and developing peptides as viral entry inhibitors. Such molecules represent a promising strategy against enveloped viruses with class 1 fusion proteins such as Nipah virus, Hendra virus, Ebola virus, and other paramyxoviruses, simian immunodeficiency virus, feline immunodeficiency virus, and respiratory syncytial virus. [43] [44] [45] [46] The HR regions of SARS-CoV-1 and SARS-CoV-2 S protein share a high degree of conservation, and such fusion inhibitors have potential applications in preventing SARS-CoV-2 entry.

Small molecule entry inhibitors, on the other hand, are reported to target the RBD. Compared to peptides, proteins, and biologics, small molecules have several advantages due to lower production costs, improved pharmacokinetics, stability, and dosage accuracy. Sarafianos et al. identified the oxazole-carboxamide derivative SSAA09E2 (1; Figure 4 ) as an entry inhibitor against SARS-CoV-1 by screening a chemical library composed of 3000 compounds. 47 This inhibitor directly blocks ACE2 recognition by interfering with the RBD with an EC 50 value of 3.1 µM and a 50% cytotoxic concentration (CC 50 ) value of greater than 100 µM, not affecting ACE2 expression levels. 48 Xu et al. 49 identified two small molecules, TGG (2; Figure 4 ) and luteolin (3; Figure 4 ), that can bind avidly to the SARS-CoV-1 S2 protein and inhibit its entry into Vero E6 cells (EC 50 and block viral entry into host cells. 51 Imatinib (6; Figure 4 ), an Abelson kinase inhibitor, could inhibit CoV S protein-induced fusion with an EC 50 value of 10 µM and showed no cytotoxic effects in Vero cells up to 100 µM concentration. 52, 53 2.2 | Inhibitors targeting the cellular receptor

The genetic code of SARS-CoV-2 shares noticeable similarities with SARS-CoV-1, which caused the SARS epidemic in 2002. 26, 54 More importantly, both viruses have identical mechanisms of infection. SARS-CoV-1 uses the host's ACE2 as a portal to infect cells, which has high expression in the vascular endothelium 55 and the lung, particularly in type 2 alveolar epithelial cells. 56 SARS-CoV-2 shares 76% of its spike (S) protein with SARS-CoV-1. Despite a few amino acid differences in its RBD compared to the SARS-CoV-1 S protein, the SARS-CoV-2 S protein binds to ACE2

with even greater affinity 27 offering an explanation for its greater virulence and preference for the lung.

ACE, a highly glycosylated type I integral membrane protein, is an essential component of the reninangiotensin (Ang) system, which controls blood pressure homeostasis. Both ACE1 and ACE2 cleave Ang peptides.

However, they differ markedly: ACE1 cuts and converts the inactive decapeptide Ang I into the octapeptide Ang II by removing the dipeptide His-Leu. This Ang II induces vaso-and bronchoconstriction, increased vascular permeability, inflammation, and fibrosis, thus promoting acute respiratory distress syndrome (ARDS) and lung failure in patients infected with SARS-CoV-1 or SARS-CoV-2 57 ( Figure 5 ). Therefore, ACE-inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) could block the disease-propagating effect of Ang II. [58] [59] [60] ACE2, on the other hand, is a zinc-containing metalloenzyme, and shares merely 42% of its amino acid sequence with ACE1. 61 It cleaves only one amino acid residue (Leu or Phe) from Ang I and Ang II, respectively, generating Ang (1-9) and Ang (1-7) (a vasodilator) ( Figure 5 ). Thus, ACE2 has been considered a potential therapeutic target for cardiovascular diseases.

Virtual screening combined with a molecular docking approach targeting the ACE2 catalytic site with around 140 000 compounds led to the identification of inhibitor N-(2-aminoethyl)-1 aziridine-ethanamine (7; Figure 6 ) with an IC 50 value of 57 µM and a K i of 459 µM. However, no information about the cytotoxicity of this compound is available so far. 62 Chloroquine (8; Figure 6 ) is a relatively safe, cheap, and effective medication for the treatment of malaria and amebiasis. Savarino et al. 63 reported its antiviral effects. At a molecular level, it increases late endosomal and lysosomal pH, resulting in impaired liberation of virions from endosomes or lysosomes. The virus is therefore unable to release its genetic material into the cell and replicate. 64, 65 Furthermore, they hypothesize that chloroquine might block the production of proinflammatory cytokines (such as IL-6), thereby blocking the pathway that subsequently leads to ARDS. 63 Chloroquine is reasonably active in vitro against SARS-CoV-1, MERS-CoV, and SARS-CoV-2. It was found to inhibit SARS-CoV-2 with an EC 50 value of 5.47 µM in vitro. 66 Antiviral activity against SARS-CoV-1 was reported with an IC 50 of 8.8 μM in Vero cells, but it is unclear how this translates into activity in respiratory epithelial cells and in vivo. 67, 68 Mechanistic studies of chloroquine for SARS-CoV-1 infection revealed that it could also weaken the interaction between the RBD of SARS-CoV-1 and ACE2 by interfering with terminal glycosylation of ACE2, thereby reducing its affinity to SARS-CoV-1 S. 69 During the SARS-CoV-2 pandemic, chloroquine has been recommended by Chinese, South Korean, and Italian health authorities for the experimental treatment of COVID-19, 70,71 despite contraindications for patients with heart disease or diabetes. 72 However, health experts and agencies like the US FDA and European Medicines

Agency warned against broad uncontrolled use after reports of misuse of low-quality versions of chloroquine phosphate intended for fish.

Hydroxychloroquine (9; Figure 6 ) is being studied as an experimental treatment for COVID-19. 73 However, the benefits of treatment with this drug are unclear. 74 Hydroxychloroquine was found to inhibit SARS-CoV-2 with an EC 50 value of 0.74 µM in vitro. 66 Some studies imply synergistic effects of hydroxychloroquine and azithromycin. Azithromycin is active in vitro against Zika and Ebola virus 75, 76 and can be used to guard against life-threatening bacterial superinfections when administered to patients suffering from viral infections. 77 A small study that compared hydroxychloroquine monotherapy and combination treatment with azithromycin found a significant advantage of the combination. While evaluating the efficacy of therapeutic intervention with hydroxychloroquine as monotherapy and its impact in combination with azithromycin, the number of patients testing negative in polymerase chain reaction (PCR) tests was substantially different in the two groups with 100% of patients cured (6 days post inclusion) in the combination arm of the study versus 57% in the monotherapy group. At the same time, 12% of patients in the control group receiving only standard care were cured. 78, 79 The WHO declared on 18 March that chloroquine and its derivative hydroxychloroquine will be among the four medicines studied in the solidarity clinical trial 80 for the treatment of COVID-19. In April 2020, the US National Institutes of Health (NIH) also commenced a study with the drug for treating COVID-19 patients. 81 The recent clinical trial involving 96 032 patients with COVID-19 concluded that it was unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or in combination with a macrolide such as azithromycin (or clarithromycin). 82 The study actually reported decreased survival rates for patients treated with each of these drug regimens. Additionally, patients had an increased risk of developing ventricular arrhythmia under treatment. However, still more evidence is needed to adequately assess the drugs' risks or benefits for the treatment or prevention of COVID-19 (it is important to note that chloroquine and hydroxychloroquine are still considered safe treatment options in certain autoimmune diseases and malaria). Besides, the WHO announced the premature pause of its clinical trials using hydroxychloroquine as a safety precaution on 24 May 2020.

On a different note, it was found that ACE2 undergoes proteolytic shedding; releasing an enzymatic ectodomain during viral entry. 83 A disintegrin and metalloproteinase (ADAM), also known as TNF-α converting enzyme (TACE), assisted the shedding regulation of ACE2. Inhibition of this enzyme led to reduced shedding of ACE2.

GW280264X (10; Figure 6 ) was found to be a specific inhibitor of ADAM-induced shedding of ACE2 at 1 nM. 84 Two TACE inhibitors, TAPI-0 (11) and TAPI-2 (12; Figure 6 ), reduced ACE2 shedding, with IC 50 values of 100 and 200 nM, respectively. 83 MLN-4760 (13; Figure 6 ) inhibited the catalytic activity of ACE2 with an IC 50 of around 440 pM. 85 This is the most potent and selective small-molecule inhibitor against soluble human ACE2 described to date, thus making it a very promising candidate for SARS-CoV-2 interference. It binds to the active site zinc and emulates the transition state peptide. However, no antiviral data for this compound is available at this time.

The interference of a virus-host cell fusion, which is mediated by the viral S protein to its receptor ACE2 on host cells, may be a viable prevention strategy. Umifenovir (14; brand name Arbidol), a broad spectrum antiviral drug used against influenza, prevents viral entry by inhibiting virus-host cell fusion. 86 It is currently being investigated in a clinical trial for the treatment of SARS-CoV-2. 87, 88 Do ACEis or ARBs amplify SARS-CoV-2 pathogenicity and aggravate the clinical course of COVID-19? After ACE2 was recognized as the SARS-CoV-2 receptor, 14, 29 speculations emerged about potentially negative consequences F I G U R E 6 Inhibitors for SARS-CoV-1 and 2 targeting ACE2. ACE, angiotensin-converting enzyme; SARS-CoV, severe acute respiratory syndrome coronavirus of ACEi or ARB therapy in COVID-19 patients. This theory caused confusion in the public and alarmed patients taking these medicines. One report said that the expression of ACE2 was increased in patients with heart disease compared to healthy individuals. It was also insisted that ACE2 expression could be increased by taking ACEis and ARBs, 89 although there is no supporting report of this happening in the lungs.

In another report, it was suggested that patients suffering from high blood pressure receiving "ACE2increasing drugs" have a higher risk for severe COVID-19, since ACEis and ARBs could elevate levels of ACE2. 90 A joint declaration by the presidents of the HFSA/ACC/AHA on 17 March 2020, 91 followed by a similar statement of the European Medicines Agency, 92 clarified that there was no scientific basis for stopping ACEi or ARB therapy. [93] [94] [95] This was in accordance with the editors of the New England Journal of Medicine. 96 In case of SARS-CoV, the experimental data showed that such medications may be beneficial rather than damaging, which led to a new therapeutic approach for lung diseases. 97 

CoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, both pathways are dependent upon receptor binding. 98, 99 The clathrin-mediated pathway involves the binding of CoV S protein to the host receptor followed by the internalization of vesicles that maturate to late endosomes. Acidification of the endosome promotes the H +dependent activation of cellular cathepsin L proteinase in late endosomes and lysosomes, which cleaves and activates the S protein, thus initiating viral fusion. Recent research shows that in addition to ACE2 SARS-CoV-2 can also use the host cell receptor CD147 to gain access into host cells. 100 Membrane fusion is also the crucial step for the CoV life cycle in the nonclathrin/endosomal route, in which host proteases such as cathepsin L, TMPRSS2, and TMPRSS11D (airway trypsin-like protease) cut the S protein at the S1/S2 cleavage site to activate the S protein for membrane fusion. 101 Interference with this process by targeting these proteases could become an attractive strategy for combating CoV infections. A recent study confirms the role of TMPRSS2 for the viral life cycle in SARS-CoV-2-infected VeroE6 cells. 5 Furin (a serine endoprotease) activates MERS-CoV to initiate the nonclathrin mediated membrane fusion event. 102 The neurotransmitter receptor blockers chlorpromazine (15) , promethazine (16) , and fluphenazine (17; Figure 7 ), were reported to inhibit MERS-CoV and SARS-CoV-1 most probably by impeding S protein-induced fusion. 103 Chlorpromazine, a clathrin-mediated viral entry inhibitor, was already described to inhibit human CoV-229E, hepatitis C virus, infectious bronchitis virus, as well as mouse hepatitis virus-2 (MHV2). 104 Recently, K11777 (19; Figure 8 ), a cysteine protease inhibitor, was shown in tissue cultures to inhibit SARS-CoV-1 and MERS-CoV replication in the subnanomolar range. 110, 111 Future tissue culture and animal model studies should be conducted to clarify, whether its antiviral activity is mediated by targeting TMPRSS2.

Teicoplanin is a glycopeptide antibiotic used to prevent infections with Gram-positive bacteria like methicillinresistant Staphylococcus aureus and Enterococcus faecalis. It was found that teicoplanin inhibits the entry of PILLAIYAR ET AL.

SARS-CoV-1, MERS-CoV, and Ebola virus by specifically targeting cathepsin L. 112 This knowledge has also been used to block the entry of new SARS-CoV-2 pseudoviruses with an IC 50 value of 1.66 µM. Therefore, teicoplanin could be considered a potential candidate for the treatment of COVID-19. 113 

Human cathepsin L is a cysteine endopeptidase and plays a key role for infection efficiency by activation of the S protein into a fusogenic state to escape the late endosomes. Targeting this protease with small molecules could interfere with virus-cell entry and therefore be a possible intervention strategy for CoV infection. 114 Bates et al. II (residues 102-184), which are β-barrel domains that shape the chymotrypsin-like structure, while domain III (residues 201-306) is made up by α-helices. 124 The CoV M pro active site uses a catalytic dyad (Cys145-His41), in which cysteine acts as the nucleophile in the proteolysis while histidine behaves as general acid-base. The peptide substrate or inhibitor binds in a cleft between domains I and II. 125 As far as the development of new therapeutics against SARS-and MERS-CoV infection is concerned, efforts have mainly focused on protease inhibitors. These enzymes are highly attractive drug targets because they are so essential to the virus. Peptides, peptidomimetics, and even small molecules can inhibit them, which leads to markedly reduced viral transmission and pathogenicity. Although most of the reported molecules display only weak anti-CoV activity, several of studies elucidated structure-activity relationships that can be used to further improve their activity. 100,126-128

To date, no approved drugs or vaccines are available for treating a coronavirus infection. In a race to identify chemotherapeutic options, various approaches, such as chemical synthesis, testing of natural products, and virtual screening of compound libraries, have been used. The systematic design of inhibitors of CoV M pro was essentially based on the enzyme's substrate. In general, a substrate can be transformed into a good inhibitor by modifying part of its sequence such that it binds to the catalytic cysteine in either a reversible or an irreversible manner. Peptide inhibitors are designed by attaching a reactive group (also known as warhead group) to peptides that mimic the natural substrate. The partial peptide substrate sequence for SARS-CoV-1 M pro is mentioned in Figure 10 ,

indicating the specific subsite of each amino acid residue.

The disclosure of the first crystal structure of the SARS-CoV-1 M pro in complex with a peptidic inhibitor Cbz-Val-Asn-Ser-Thr-Leu-Gln-chloromethyl ketone (also known as hexapeptide chloromethyl ketone; 28) 125 provided clues for the substrate-based design. Although it is a substrate analog for the porcine transmissible gastroenteritis CoV (TGEV) M pro , it offers a structural explanation for the P1-Gln entering into the specific subsite S1 pocket and decreased P2-leucine specificity in the hydrophobic S2 site of SARS-CoV-1 M pro . Additionally, rupintrivir (29; AG7088), a peptidomimetic inhibitor of human rhinovirus 3C protease is oriented similar to inhibitor 28 in the binding pocket of TGEV M pro . 129 These two molecules became prototype compounds for the development of SARS-CoV-1 M pro inhibitors.

Compound 29 was only weakly active against SARS-CoV-1 M pro (IC 50 , 800 µM) also in cellular antiviral assays. 130 However, systematic structural modifications led to a series of analogs that show moderate to good activity. 131 For example, compound 30 ( Figure 11 ), in which the P1-lactam was replaced by a phenyl ring, showed moderate activity. Compound 31, in which the larger P2 p-fluorophenyl was replaced with a phenyl group, was even more effective. By taking 29 as a lead, Ghosh et al. designed new molecules mainly focusing on the replacement of the large P2 p-fluorobenzyl group. Two of the resulting structures with P2-benzyl (32) and prenyl (33) moieties showed decent inhibitory potencies at both enzymatic (K inact , 0.014 and 0.045 min −1 , respectively) and

cell-based (IC 50 , 45 and 70 µM) assays. 132 Besides, no cytotoxicity was observed for these compounds up to 100 µM concentration. However, 32 and 33 were inactive at MERS-CoV M pro . 133 The same research group further modified the molecule with the introduction of P4 Boc-serine, to establish additional hydrogen bond interactions as described in compound 34 (IC 50 , 75 µM). Unfortunately, the activity of the resulting compound was not improved. Further modification of the isobutyl group in compound 34 to isoprenyl group in compound 35 displayed potent activity with K i = 3.6 µM ( Figure 11 ). 14 On the other hand, Yang et al. 134 reported a series of peptide inhibitors with a greater inhibitory potency. In general, they systematically changed the backbone of inhibitor 29. As a result, they were able to identify more specific residues for each subsite (compounds 36-38; Figure 12 ): At first, the P1-lactam ring was identified as a more specific moiety for the S1-site, forming multiple hydrogen-bond interactions with the enzyme as can be seen in the crystal structure (36); P2-leucine showed a fourfold increased inhibitory activity when compared to the P2-phenylalanine or -4-fluorophenylalanine (37) . A lipophilic tert-butyl residue was recognized to be a better P3-moiety than the P3-valine (38) . Finally, the replacement of P4-methylisoxazole with a benzyloxy group was the best option for activity enhancement (compare 29 vs 36). They all showed moderate to high antiviral activity against HCoV-229E in cell-based assays.

Shie et al. 131 reported another series of peptide inhibitors with comparatively reduced molecular weight to increase drug-like properties. These pseudo-C2-symmetric inhibitors consist of a Phe-Phe-dipeptidic α,β-unsaturated ester. One of these inhibitors (39) had an outstanding inhibitory activity with an EC 50 value of 0.52 µM (see Figure 12 ). Besides, it displayed remarkable antiviral activity with an EC 50 value of 0.18 µM. Structurally, the presence of 4-dimethylamine on the phenyl ring was found to be crucial for activity enhancement.

Another peptidic drug with a Michael acceptor was N3 (40) , which was reported to inhibit SARS-CoV-1 3CL pro SARS-CoV-2 shares only 82% of its genome with its relative SARS-CoV-1. However, essential viral enzymes of both species show sequence similarities of greater than 90%. 137,139-142 SARS-CoV-2 3CL pro is highly similar to SARS-CoV-1 3CL pro , sharing 96% of its sequence. Therefore, one could expect that SARS-CoV-1 M pro inhibitors are active against SARS-CoV-2 M pro . Compound 40 was found to be active against SARS-CoV-2 M pro and its value of kobs/[I] for the COVID-19 virus M pro was determined to be 11 300 ± 880 M −1 ·s −1 . 143 Peptide N3 was cocrystalized with SARS-CoV-1 M pro at 2.1 Å resolution (see Figure 13 ). Its binding mode to SARS-CoV-2 M pro is highly similar to that of other CoV main proteases. Some key features include the Cys-His catalytic dyad and the substrate-binding pocket situated in a gap between domain I and II.

In general, inhibitors possessing a Michael acceptor group as a warhead moiety could form an irreversible (covalent) bond with the catalytic cysteine residue in the following manner ( Figure 14) : First, the cysteine residue undergoes 1,4-addition at the inhibitor's Michael acceptor group (warhead). Rapid protonation of the α-carbanion from His-H + leads to the covalent bond formation between the warhead of the inhibitor and the cysteine residue.

Although the above-described inhibitors with 1,4-Michael acceptors (e.g., α,β-vinyl ethyl ester, -CH═CH-C

(O)-OEt) showed enzymatic or cell-based in-vitro activities, they can be cleaved to their carboxylic acids by plasma esterases; for instance, AG7088 (29) was inactive in the plasma of rodents and rabbits. 144, 145 Therefore, scientists explored different reactive groups that are stable in vivo. shown in Figure 16 . Among them, 49 was moderately more active against SARS-CoV M pro when compared to 46. 148 The X-ray structure of M pro in complex with 49 revealed that the P2-decahydroisoquinoline moiety was fittingly placed in the S2-subsite, while the P1-imidazole moiety occupied the S1-subsite. With these key residues located appropriately in their respective pockets, the terminal functional group fits tightly into the active site.

This group further extended their study to find inhibitors that interact with S2 to S4 subsites. Taking as shown in example 52. 149 The resulting 52 showed more than twofold increased M pro inhibitory activity compared to 49 . This indicates that the additional interactions at S2-S4 sites enhance inhibitory activity.

Rather recently, the same research group explored the ability of octahydroisochromene to interact with the hydrophobic S2 pocket as an innovative P2-moiety. 150 To identify the best specific configuration, all possible diastereomers were evaluated. It was found that the molecule with (1S,3S)-octahydroisochromene 53-56 could secure the optimal position of the P1-imidazole as well as the aldehyde functional group at the active site.

Additionally, the N-butyl side chain attached to the 1-position of the fused ring system was recognized to be important for establishing hydrophobic interactions.

In 2018, Groutas et al. 151 Compound 63 was identified as SARS-CoV M pro inhibitor with an IC 50 value of 1.95 µM (Figure 19 ). 156 Taking 63 as a lead, aided by its X-ray structure in complex with SARS-CoV-1, HCoV-NL63, and coxsackievirus M pros , systematic structural modifications were investigated, focusing on the P2-moiety. As a result, the replacement of P2-phenyl with P2-cyclohexyl (64) was found to be the best substitution, while P2-cyclopentyl (65) showed similar potency against the enzyme SARS-CoV-1 M pro . In Huh7 cells, 64 also showed strong antiviral activity with an EC 50 at the surface of each protomer, between domains I and II. The thioketal that resulted from the nucleophilic Cys145 attacking the inhibitor, is stabilized by a H-bond from His41, whereas the amide oxygen of 67 accepts a H-bond from the main-chain amides of Gly143, Cys145, and in part, Ser144 that make up the cysteine protease's canonical oxyanion hole. 157 The P1 lactam moiety is deeply embedded in the S1 pocket where the lactam nitrogen donates a three-center H-bond to the main chain oxygen of the Phe140 and the carboxylate of Glu166. The carbonyl oxygen forms a H-bond to His163. The P2-cyclopropyl moiety fits into the S2 subsite. The P3-P2 pyridone moiety occupies the space normally filled by the substrate's main chain. The Boc group is not situated in the canonical S4 site, rather it is located near Pro168, which explains why the removal of the Boc group as in 68

weakened the inhibitory activity.

It was envisioned that a fluorinated ketone moiety could be utilized as a warhead for targeting proteases, because it forms a thermodynamically stable hemiketal or hemithioketal after nucleophilic attack by Ser-OH or Cys-SH residues, which are present in the active sites of serine or cysteine proteases, respectively (see Figure 22 ). was exchanged for a variety of functional groups. 161 The study determined N-arylglycyl to be the optimal P3moiety. Compound 72 displayed the best inhibitory activity. Docking studies of 72 to the protease highlighted the amino hydrogen of the P3-N-phenyl glycyl forming a H-bond with backbone Glu166 of M pro , in addition to the best P2-leucine and P1'-benzthiazole moieties (see Figure 23A ). Further structural optimization at the P3-N-arylglycyl moiety found the indole-2 carbonyl group to be one of the best P3-moeities, thus reaching inhibitors with low nanomolar potency, for example 73 (K i , 0.006 µM) against SARS-CoV-1 M pro . 162 

Benzotriazole esters (88-91; Figure 26 ) were discovered as novel nonpeptidic irreversible inhibitors of SARS-CoV-1 M pro . 168 bound more strongly to SARS-CoV-1 M pro than to papain protease, while etacrynic acid ester 104 was more active at papain protease (K i , 3.2 µM) than at SARS-CoV-1 M pro (K i , 45.8 µM; Figure 28 ). SAR studies suggested that chloro substituents were necessary for protease inhibition. Docking studies of 105 to M pro revealed that it forms hydrogen bonds with Gln189, Glu166, Thr190, and Gln192 with its terminal amino group. The Michael system carbonyl group interacts with Gly143, and the reactive double bond remained next to the Cys145 sulfur.

Previously, isatin (2,3-dioxoindole) derivatives were observed to inhibit rhinovirus 3C protease. 176 

The modification of 110, identified by high-throughput screening (HTS; Figure 29 ), led to pyrazolone and pyrazole derivatives 111 and 112 as SARS-CoV-1 M pro inhibitors. 179, 180 Taking these as leads, Ramajeyam et al. 181 reported compounds 112-114 to be the best-performing inhibitors of the series(IC 50 5.5, 6.8, 8.4 µM, respectively).

They also observed moderate inhibitory activity against CVB3 3C pro . Structure-functionality analyses illustrated that the benzylidene ring next to pyrazolone C4 in addition to electron-withdrawing groups, favors inhibitory activity. Molecular modeling studies of 112 predicted that for its inhibitory function, the N1-phenyl residue in the M pro S1 site as well as the carboxyl benzylidene moiety in the S3 pocket are important. SAR studies focusing on the benzotriazole moiety of 129 were performed to improve activity. The replacement of this group with 4-phenyl-1,2,3-triazole (as in 130) was somewhat tolerated (IC 50 of 11 µM; Figure 32 ). To cut overall molecular weight of the inhibitors, P3-truncation was performed, which led to potent derivatives bind to M pro . Antiviral activity assays, using real-time reverse transcription-PCR, indicated that ebselen and inhibitor "N3" (40; Figure 12 ) had the strongest antiviral effects. Ebselen displayed an EC 50 value of 4.67 µM, and "N3" showed an EC 50 value of 16.77 µM in a plaque-reduction assay. Ebselen's IC 50 value for SARS-CoV-2 M pro was reported at 0.67 µM. The activity data of remaining compounds is summarized in Figure 35 .

Ebselen has been studied for an array of diseases and has a very low toxicity. [191] [192] [193] Its safety has been demonstrated in clinical trials. 191, 192, 194 It can therefore be considered a promising molecule for the treatment or prevention of CoV infections. 

Along with the M pro , papain-like protease (PL pro ) also cleaves polyproteins which is an important process for viral replication. PL pro cleaves at the first three positions creating three nonstructural functional proteins (nsp1-nsp3).

In particular, nsp3 is central for the generation of the viral replication complex. The multifunctionality of PL pro in deubiquitinating, de-ISGylation (ISG: interferon-stimulated gene), 195, 196 and in the evasion of the innate immune response make PL pro an attractive antiviral drug target.

PL pro is a cysteine protease and its active site contains a catalytic triad composing of Cys112-His273-Asp287.

Cys112 behaves as a nucleophile, and His273 is a general acid-base. Asp287 helps His273 to align perfectly, thus promoting His to deprotonate Cys-SH.

Ghosh et al. 197 activities.

Next, the same group studied the SARs for compound 158 further. This led to the discovery of compound 165

with high PL pro inhibitory activity of SARS-CoV-1 (IC 50 , 0.32 µM) and antiviral activity (EC 50 , 9.1 µM) in Vero cells. 199 The mode of action of 165 was found to be a noncovalent, competitive inhibition of PL pro . Unlike the previous series, the stereochemistry at the α-methyl group did not make a significant difference in inhibition of Chou et al. 201 identified thiopurine (171) and 6-thioguanine (172) as SARS-CoV-1 PL pro inhibitors by the screening of a library containing 160 compounds. The thiocarbonyl group was important for PL pro inhibition.

However, the toxicity of these anticancer agents limits their therapeutic utility as anti-SARS agents. Disulfiram (151; Figure 35 ) was also reported as a SARS-CoV-1 PL pro inhibitor (IC 50 , 24.1 µM), 205 probably by reacting with the active site cysteine, thereby covalently modifying the enzyme target, as was reported for other targets.

The ability to produce new RNA copies from available template molecules is necessary for life on earth. RNA polymerases are therefore found in all living cells as well as many viruses. RdRP are essential enzymes to all RNA viruses, as they catalyze the synthesis of new RNA from a given RNA template. 206 Due to their importance for viral life cycles, and their high conservation among different RNA viruses, they have been attractive drug targets for antiviral therapy for a long time.

F I G U R E 37 Broad spectral PL pro inhibitors from different sources. PL pro , papain-like protease; SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoV-2 also uses an RdRP to replicate its genome within the host cell. Three nonstructural viral proteins (nsp) form its replication/transcription complex, with nsp12 forming the catalytic subunit. Bound to it are nsp7 and nsp8-accessory factors that facilitate template binding. [207] [208] [209] Their individual structures and that of the complex have been solved. [210] [211] [212] [213] [214] Interestingly, the only nsp that interacts directly with RNA seems to be nsp12, whereas nsp7 and nsp8 are needed to increase its efficiency. 210, 215 RdRP is the target of inhibitors like remdesivir (178) , galidesivir (179) , ribavirin (180) , favipiravir (181) , and EIDD-2801 (182) . These molecules have shown promise for the treatment of COVID-19 patients. 87, [216] [217] [218] (For structures and biological data see Figure 38 )

Remdesivir is a 1'-cyano-substitued adenine C-nucleoside analog prodrug. The prodrug strategy used is similar to that of the FDA-approved anti-hepatitis C drug sofosbuvir (183; see Figure 38 ). Upon its diffusion into cells, the phosphoramidate undergoes an intracellular conversion process that results in the formation of the triphosphate active metabolite (RTP). The triphosphate is recognized as adenine by viral RdRP, which causes heavy disruptions in RNA synthesis.

The exact molecular mechanism of remdesivir's action against SARS-CoV-2 has recently been elucidated by Yin et al. 219 Galidesivir is another C-nucleoside analog that resembles adenosine. However, the base is not linked to a ribose, but to an aza-sugar. Although it is recognized as adenosine by RdRP, its properties are different enough to cause a disruption in chain elongation. Galidesivir has been used in the treatment of Ebola and Marburg virus infections, and in vitro studies against SARS-and MERS-CoVs have suggested efficacy against CoVs. 221 Therefore, it is a likely future anti SARS-CoV-2 agent, and currently being studied in clinical trials. 222, 223 Ribavirin is a nucleoside analog, which shows structural similarity to guanosine. But guanosine's 6-membered ring is only hinted at by the amide group. As such, it is incorporated by viral RdRPs, but interrupts RNA polymerization. 224 It is an approved drug in most countries and used against a variety of viral infections. Although its efficacy against SARS-CoV-2 has not been determined in large clinical trials, ribavirin has shown some promise in the treatment of COVID-19 patients. 225 Favipiravir (Avigan®) is an approved antiviral drug for the treatment of influenza in Japan and China. It is a pyrazinamide derivative that has shown some activity against a variety of RNA viruses. 226 Favipiravir inhibits viral RdRP via its similarity to guanine. After biotransformation into its active metabolite, favipiravir-ribofuranosyl-5'triphosphate, it is incorporated into newly synthesized RNA by RdRP, leading to premature chain termination 227 similar to remdesivir's mode of action. Favipiravir is currently being studied around the world as a treatment option against COVID-19.

Very recently, Sheahan et al. 228 reported the discovery of EIDD-1931 and its orally bioavailable prodrug EIDD-2801. These nucleoside analogs have shown remarkable potency against SARS-CoV-2 and other related CoVs in vitro and in vivo, with IC 50 values in the low nanomolar range, outperforming remdesivir 3-10-fold. The reason for this increased potency could be additional interactions with viral RdRP involving the N4-hydroxyl group of the cytidine ring. 219 The efficacy of EIDD-2801 in COVID-19 patients is being evaluated in a clinical trial. 229 Remdesivir and other potential RdRP inhibitors 230 are currently being studied in clinical trials around the world, but even though preliminary results appear promising, it is too early to assess their clinical value against COVID-19. 231 Several studies also described the combination of IFNs with antiviral drugs like ribavirin (180) or lopinavir-ritonavir for treating SARS. 232, 233 In 2004, SARS patients in an open-label study had better clinical outcomes when treated with ribavirin in combination with lopinavir-ritonavir (400 and 100 mg, respectively) than the control group receiving only ribavirin. 227 A study in SARS patients found that viral replication could not be blocked at ribavirin concentrations achievable in human serum. 234 Nevertheless, the combination of ribavirin with IFN-β had a synergistic effect on the inhibition of SARS-CoV-1 replication. The effects of PEGylated IFN together with ribavirin against SARS-CoV-2 are being studied in clinical trials. 87 Nitazoxanide (178; Figure 39 ), a broad-spectrum antiparasitic drug, was reported to inhibit SARS-CoV-2 (EC 50 , 2.12 μM in Vero E6 cells). 215 It is also an IFN-inducing agent, and it is being studied for treating a wide range of infections.

The antiarrhythmic drug amiodarone (179, Figure 39 ) also inhibited SARS-CoV-1 replication in infected Vero cells. 235 The drug appears to alter the endocytotic pathway, thus inhibiting endosomal viral entry.

Glycyrrhizin inhibited viral replication in Vero cells with an EC 50 value of 300 mg/L, possibly by blocking viral entry as well. 232 As nitric oxide (NO) has been associated with antiviral activity, the NO donor, S-nitroso-N-acetylpenicillamine (180; Figure 39 ) was reported to inhibit SARS-CoV-1 replication in a dose-dependent manner. 236 In a search for potential antiviral agents against SARS-CoV-1, the screening of a library of 8000 approved drugs identified cinanserin (150; Figure 39 ), a serotonin antagonist, as a potential inhibitor of SARS-CoV-1 targeting its M pro with IC 50 value 4.0 µM. 189 A virtual screening and docking study identified the calmodulin antagonist calmidazolium as a SARS-CoV-1 M pro inhibitor (K i , 61 µM). 237 In 2014, Dyall et al. reported an array of pharmaceutical drugs with antiviral activity against MERS-CoV, and SARS-CoV-1 ( Table 2 , chemical structure of all drugs were indicated in Figure S1 ). 121 The agents were grouped according to their modes of action. Hits inhibited both investigated CoVs.

In particular, the protein-processing inhibitors cycloheximide and anisomycin showed strong inhibitory activities against both CoVs. The HIV protease inhibitor lopinavir was more effective against SARS-CoV-1 than against MERS-CoV. The antidiarrheal agent loperamide showed moderate inhibitory activitiy against both CoVs. Niclosamide (181; Figure 39 ), an anthelmintic drug, exhibited very potent antiviral activity against SARS-CoV-1 replication and stopped viral antigen synthesis at 1.56 μM concentrations. 238 It prevented the cytopathic effect of SARS-CoV-1 at low concentrations of 1 μM and halted SARS-CoV-1 replication with an EC 50 less than 0.1 μM in Vero E6 cells. 188 Famotidine has been proposed as a therapeutic against COVID-19, and a clinical trial is underway. 245 It is used to treat peptic ulcers and gastroesophageal reflux disease, among others. Cimetidine is a similar drug and has also been suggested as a treatment for COVID-19.

Dipyridamole was proposed as a treatment for COVID-19 as well, and a clinical study is being conducted. 246 It is a nucleoside transport and PDE3 inhibitor that prevents blood clot formation.

Sildenafil was proposed as treatment for COVID-19, and it is currently being investigated in a small trial. 247 It is a medication used to treat erectile dysfunction and pulmonary arterial hypertension.

Fenofibrate and bezafibrate have been suggested for the treatment of COVID-19. Fenofibrate is a blood lipidlowering medicine of the fibrate class. 248, 249 Bezafibrate is a related lipid-lowering agent.

The HIV-protease inhibitor nelfinavir (183; Figure 39 ) strongly inhibited replication of SARS-CoV-1 in Vero cells with an EC 50 value of 0.048 µM. It was suggested to exert its effect at the post-entry step of SARS-CoV-1

infection. 250 Recently, Yamamoto et al reported that nelfinavir also potently inhibited replication of SARS-CoV-2 among nine other Anti-HIV drugs tested (IC 50 , 1.13 µM; CC 50 , 24.32 µM; SI = 21.52). 251 The measured serum concentrations of nelfinavir were 3-6 times higher than the reported EC 50 

The SARS-CoV-2 outbreak has caused worldwide disruption and was recently declared a global pandemic by the World Health Organization (WHO) owing to its rapid spread and high fatality rate. As there is no effective treatment to date, the number of infections continues to rise globally. This has led numerous research groups around the world to prioritize the identification and development of new therapeutics against COVID-19.

Although it is often considered the most promising method to prevent or contain future coronavirus outbreaks, an all-round anti-CoV vaccine is possibly a long way away. Small molecule drugs have the potential to be effective, rapidly produced, and widely available. Indeed, several small molecules have been investigated and advanced to clinical trials for the treatment of COVID-19, selected drug candidates are indicated in Table 3 (https://covid-19.heigit.org/clinical_trials.html).

As outlined in this review, inhibitors of important viral enzymes or structures, such as M pro , PL pro , or RdRP have displayed encouraging activity against various human-infecting CoVs. Since, both contagious viruses, SARS-CoV-1 and SARS-CoV-2, have a similar mechanism of infection; and both share the same human receptor, ACE2, for viral entry, for example-already developed inhibitors against the former could potentially be used to combat the latter. But despite the efficacy demonstrated by many inhibitors of SARS-CoV-1, no specific prophylactic or postexposure therapy is currently available.

The first step in the viral life cycle is the viral entry. It represents an attractive intervention point by blocking the RBD-ACE2 interaction or the virus-cell membrane fusion event. A large number of inhibitors, including peptides, antibodies, small-molecule compounds, and natural products have been identified to hamper viral entry.

Some of the peptides and antibodies displayed substantial anti-SARS activity and are therefore considered promising entry inhibitors with high potencies in the low micromolar range. Despite the apparent match of SARS-CoV-2 S and ACE2, other possible viral entry receptors should not be left unexplored. The glucose-regulated protein 78 (GRP-78, aka HSPA5), for instance, is employed as a coreceptor for entry by several viruses, including bat-CoVs and MERS-CoV, 260 and a study predicted that SARS-CoV-2 S might utilize this mechanism as well. 261 Elevated levels of GRP-78 in COVID-19 patients suggest a supplementary link. 262 Although as of yet unconfirmed, the development of therapeutics against additional targets like GRP-78 should receive due attention.

Viral proteases are another very important target for the development of antiviral therapies, as they are directly involved in the viral replication processes. Especially the M pro is one of the best-characterized viral targets, and numerous medicinal chemistry efforts have been already reported for the past outbreaks of SARS-1 and MERS. Main proteases are highly conserved among other CoVs, which allows the development of broad spectral antiviral agents. Moreover, no human protease analog to the M pro is known. Thus, drugs targeting M pro could be highly virus-selective and safe.

In light of the urgency of the current outbreak, repositioning of already approved drugs is becoming a popular approach due to the availability of toxicity and safety data. Drug repurposing has become fashionable, promising quick solutions to complicated questions. Old and, presumably, safe drugs are proclaimed miracle cures. The reality is a different one: Widely employed broad-spectrum antiviral drugs, such as (hydroxy)chloroquine, favipiravir, ribavirin, or umifenovir were reported to be effective against SARS-CoV-2, but could not convince in clinical trials yet. Clinicians are faced with an avalanche of contraindications and a myriad of case reports to choose the right drug. The drug repositioning strategy is, therefore, not a sound scientific path to a cure. At best, it can provide a basis for extensive future research in all related fields, including synthetic organic medicinal chemistry.

A new problem with the current COVID-19 outbreak is related to the spread of scientific information. When initial unfounded speculations about the alleged dangers of antihypertensive therapies with ACEis and ARBs were widely publicized in the media they caused great uncertainty among patients. Impetuous communications such as these can have serious consequences and should not be proclaimed carelessly. As it turns out, the benefits of continued antihypertensive therapy with these medicines in COVID-19 patients far outweigh their risks. There is even evidence of additional protective effects of ACEis and ARBs in this cohort, although the clinical relevance of this has yet to be investigated.

It is clear that governments and societies all over the world have been surprised by the recent coronavirus outbreak-as they were by the SARS outbreak in 2003 and the MERS epidemic in 2013. Human-infecting CoVs are on the rise, but quickly forgotten once life returns to normal. However, this problem will not disappear by itself, but likely increase in intensity. Viral spillover events are expected to increase in frequency as humans continue to invade new territories. We hope that, this time, the world will heed nature's warning to finance and conduct groundbreaking research on CoVs and their disease patterns. Only with a profound understanding of the viral life cycle and the affected human physiology we can prevent and control future outbreaks.

34 µM; CC 50

Ritonavir (EC 50 , 8.63 µM; CC 50 , 74.11 µM, SI = 8.59), saquinavir (EC 50 , 8.83 µM; CC 50

SI = 5.03), and atazanavir (EC

65) suppressed SARS-CoV-2 at less than 10 µM. Lopinavir, which was studied in SARS and COVID-19 patients, also potently inhibited SARS-CoV-2 replication with the highest selectivity index

identified four drugs-chloroquine (8), chlorpromazine (15), loperamide (184), and lopinavir (185)-by screening of an FDA approved drugs library (for structures, see Figure 40). 252 All of them blocked SARS-CoV-1, MERS-CoV, and HCoV-229E replication at small concentrations, suggesting potential as broad-spectrum virostatic agents

Chloroquine (8) was able to inhibit SARS-CoV-2 viral replication in vitro, but a recent study found no clinical benefit for COVID-19 patients who had received the drug 82 (the drug is discussed in detail in the section viral entry inhibitors)

It is a neuroleptic drug used against schizophrenia; 253 here, it interferes with clathrin-mediated endocytosis. Since, clathrin-mediated endocytosis is a crucial port for viral entry into the host cell, used by MHV

102 future clinical trials could help elucidate this drug's therapeutic potential against COVID-19

an opioid receptor agonist against diarrhea, 257 inhibited the replication of SARS-CoV-1

Lopinavir (185) is an HIV protease inhibitor and was previously shown to block SARS-CoV-1 M pro

analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS-CoV. 259 A series of hit compounds was identified

Saracatinib (189) was especially interesting, as it had remarkable anti-MERS-CoV activity (EC 50 of 2.9 µM, CC 50 > 50 µM)

It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src-family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS-CoV-1 (EC 50 , 2.4 µM)

Recent discovery and development of inhibitors targeting coronaviruses

An overview of severe acute respiratory syndromecoronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy

Middle East respiratory syndrome-coronavirus (MERS-CoV): an updated overview and pharmacotherapeutics

Report of the International Committee on Taxonomy of Viruses

Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies

A new virus isolated from the human respiratory tract

Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease

SARS cases with onset of illness from 1

CoV Global Summary and risk assessment

WHO Coronavirus Disease (COVID-19). Dashboard. Accessed 15

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Molecular evolution of human coronavirus genomes

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4

Human aminopeptidase N is a receptor for human coronavirus 229E

Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme

Murine encephalitis caused by HCoV-OC43, a human coronavirus with broad species specificity, is partly immune-mediated

Origin and evolution of pathogenic coronaviruses

A novel coronavirus from patients with pneumonia in China

Coronaviruses: an overview of their replication and pathogenesis

Coronavirus infections and immune responses

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A new coronavirus associated with human respiratory disease in China

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, nsp12 polymerase and nsp13 helicase

Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV

The multifunctional or moonlighting protein CD26/DPPIV

Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

Trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein

Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides

Functional importance of the coiled-coil of the Ebola virus glycoprotein

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Angiotensin-converting enzyme 2 in lung diseases

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

Activation of angiotensin converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model

Angiotensin converting enzyme 2 protects from severe acute lung failure

Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome

Quantitative mRNA expression profiling of ACE 2, a 11 novel homologue of angiotensin converting enzyme

Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

Effects of chloroquine on viral infections: an old drug against today's diseases

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Physicians work out treatment guidelines for coronavirus

Azioni intraprese per favorire la ricerca e l'accesso a inuovi farmaci per il trattamento del COVID-19

Plaquenil (hydroxychloroquine sulfate) dose, indications, adverse effects, interactions. from PDR.net

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

Evaluation of Ebola virus inhibitors for drug repurposing

Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

What are the prospects for a Covid-19 treatment? The Guardian

NIH clinical trial of hydroxychloroquine, a potential therapy for COVID-19, begins. National Institutes of Health (NIH) (Press release

Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial

Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensinconverting enzyme-2 (ACE2)

TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis

Structural basis of influenza virus inhibition by the antiviral drug Arbidol

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection (ELACOI)

COVID-19 and the cardiovascular system

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

HFSA/ACC/AHA Statement Addresses Concerns Re: using RAAS antagonists in COVID

EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic

Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial

Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade

New research on possible treatments for Covid-19

Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases

Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted

SARS coronavirus entry into host cells through a novel clathrin-and caveolaeindependent endocytic pathway

SARS-CoV-2 invades host cells via a novel route: CD147-spike protein

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2

Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner

Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry

Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway

Entry of human parechovirus

Influence of chlorpromazine on the replication of influenza virus in chick embryo cells

Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine

JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

Protease inhibitors targeting coronavirus and filovirus entry

Therapeutic development and drugs for the treatment of COVID-19

Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)

Teicoplanin potently blocks the cell entry of 2019-nCoV

A review of small molecule inhibitors and functional probes of human cathepsin L

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and Ebola pseudotype virus infection into human embryonic kidney 293T cells

Phenotypic vs. target-based drug discovery for first-in-class medicines

Emodin blocks the SARS coronavirus spike protein and angiotensinconverting enzyme 2 interaction

Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

Virus-encoded proteinases and proteolytic processing in the Nidovirales

Mechanisms and enzymes involved in SARS coronavirus genome expression

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme

Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV

Anti-SARS coronavirus agents: a patent review (2008-present)

Coronavirus main proteinase (3CL pro ) structure: basis for design of anti-SARS drugs

The structures of picornaviral proteinases

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α, β-unsaturated esters

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CL pro ) implications for nsp5 regulation and the development of antivirals

Synthesis, crystal structure, structure−activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design

Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design

From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses

In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East respiratory syndrome (MERS) coronavirus infection

MERS cases spotlight lack of research: outbreak of Middle East respiratory syndrome in South Korea is controllable, but how it infects humans is a puzzle

WHO Director-General's opening remarks at the media briefing on COVID-19

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers

Liquid chromatography-mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease

Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL pro inhibitors

Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors

Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors

Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor

Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor

Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element

Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases

Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide

Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors

Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies

Hayashi Y. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease

Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronavirus (SARS-CoV) inhibitors

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease

Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CL pro

Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors

Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease

Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters

High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase

Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro

Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors

Assessing activity and inhibition of MERS-CoV papain-like and 3C-like proteases using luciferase-based biosensors

Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase

A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods

Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors

Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors

Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays

Individual and common inhibitors of coronavirus and picornavirus main proteases

Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors

Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors

Identification, synthesis, and evaluation of new neuraminidase inhibitors

Discovery, synthesis, and structure-based optimization of a series of N-(tertbutyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl) acetamido) phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL pro inhibition

Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro

A safe lithium mimetic for bipolar disorder

Development of ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss

Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial

Winkelmann J 2-Phenyl-1, 2-benzisoselenazol-3 (2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases. US4352799A

Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing

MERS-CoV papain-like protease has deISGylating and deubiquitinating activities

Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease

Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation

Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV

Thiopurine analogs and mycophenolic acid synergistically inhibit the papainlike protease of Middle East respiratory syndrome coronavirus

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases

Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

Tentative identification of RNA-dependent RNA polymerases of dsRNA viruses and their relationship to positive strand RNA viral polymerases

The coronavirus replicase

Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates

The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent

Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer

Structural genomics of the severe acute respiratory syndrome coronavirus: nuclear magnetic resonance structure of the protein nsp7

NMR structure of the SARS-CoV nonstructural protein 7 in solution at pH 6.5

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Washington state 2019-nCoV case investigation team, first case of 2019 novel coronavirus in the United States

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

BCX4430-a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters

Chemistry and biology of SARS-CoV-2

Mechanisms of action of ribavirin against distinct viruses

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

COVID-19 first in human study to evaluate safety, tolerability, and pharmacokinetics of EIDD-2801 in healthy volunteers

Emory-discovered antiviral is poised for COVID-19 clinical trials

A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

Treatment of SARS with human interferons

Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection

Ribavirin in the treatment of SARS: A new trick for an old drug?

Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level

Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv

Amid ongoing COVID-19 pandemic, governor Cuomo accepts recommendation of army corps of engineers for four temporary hospital sites in New York. governor.ny.gov

Zone Santé-. Début d'uneétudeclinique pour tester un médicamentcontre les effets de la COVID-19 | Coronavirus. Radio-Canada

New York clinical trial quietly tests heartburn remedy against coronavirus

The world health organization international clinical trials registered organization registered platform

A Pilot Study Of Sildenafil In COVID-19-full text view

Delivering benefits at speed through real-world repurposing of off-patent drugs: the COVID-19 pandemic as a case in point

No time to waste: real-world repurposing of generic drugs as a multifaceted strategy against COVID-19

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

Role of endocytosis and low pH in murine hepatitis virus strain A59 cell entry

Mouse hepatitis virus type 2 enters cells through a clathrin-mediated endocytic pathway independent of Eps15

ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells

Small molecules targeting severe acute respiratory syndrome human coronavirus

Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro

The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection

COVID-19 spike-host cell receptor GRP78 binding site prediction

Preliminary virtual screening studies to identify GRP78 inhibitors which may interfere with SARS-CoV-2